Heparegenix Secures €21.5M for Liver Regeneration
HepaRegeniX, a clinical-stage company developing therapies for liver diseases, completed a €21.5 million financing round with Wellington Partners. The...
Promising Efficacy Reported for TLX101 Glioma Therapy
Telix Pharmaceuticals announced preliminary positive Phase 2 results for TLX101, a targeted radiation therapy for recurrent high-grade glioma (brain...
Radiance Announces First Patient Dosing in Phase 1 Trial for ROR1 ADC
Radiance Biopharma has dosed the first patient in China for a Phase 1 clinical trial of RB-164™ (SYS6005), a...
Onvansertib in RAS+ Metastatic Colorectal Cancer: Phase 2 Trial Completes Enrollment
Cardiff Oncology has completed patient enrollment in its Phase 2 CRDF-004 trial. The trial is evaluating onvansertib combined with...
Lyell’s LYL314 Gets FDA RMAT Designation for Lymphoma Treatment
Lyell Immunopharma announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 for treating relapsed and/or...
Predictive Oncology’s Novel Approach to Abandoned Drugs
Predictive Oncology leveraged its AI-driven drug discovery platform and biobank of live-cell tumor samples to identify new potential uses...
Oryzon Doses First Patient in iadademstat Trial in Small Cell Lung Cancer
Oryzon Genomics has initiated a Phase I/II trial evaluating iadademstat, an LSD1 inhibitor, combined with immune checkpoint inhibitors (atezolizumab...
Hacking the Placebo Effect: How AI Is Reshaping Clinical Trial Variability
AI is making significant strides in the rapidly evolving field of clinical trials. Dominique Demolle, CEO of Cognivia, shares...
Icotrokinra Redefines Psoriasis Treatment: Positive Phase 3 Data
Johnson & Johnson’s oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), demonstrated positive Phase 3 results in treating moderate-to-severe plaque psoriasis....
Doxypep Access Marks One Year, STI Rates Halved
MISTR, the largest LGBTQ+ sexual health platform in the U.S., reports a significant 50% drop in STI positivity rates...